Clinical trial
A Phase 1/2 Open-label, Multi-center Study to Evaluate the Safety and Clinical Activity of GSK5926371 in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)
NCT07607925 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2 Open-label, Multi-center Study to Evaluate the Safety and Clinical Activity of GSK5926371 in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)
- Lead sponsor
- GlaxoSmithKline
- Phase
- Phase 1/2
- Overall status
- Not yet recruiting
- Start date
- June 12, 2026
- Completion date
- September 24, 2029
- Enrollment
- 49 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.